SCHEMBL16084472

SCHEMBL16084472

COc1ccnc2c1nc(N)n2C1CCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 9/20 0.40
ADORA3 P0DMS8 3/20 0.40
ADORA1 P30542 3/20 0.40
ADORA2B P29275 2/20 0.40
PDE4B Q07343 2/20 0.38
MAP3K11 Q16584 2/20 0.38
CDK5 Q00535 2/20 0.37
CDK5R1 Q15078 2/20 0.37
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
CCNA1 P78396 1/20 0.37
TNF P01375 2/20 0.37
LITAF Q99732 2/20 0.37
PDE7A Q13946 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
PIK3CD O00329 1/20 0.36
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084183 0.82 ADORA3 (0.43) ADORA2AADORA3ADORA1ADORA2BPDE4B
SCHEMBL16084474 0.73 PDE4B (0.52) ADORA2AADORA3ADORA1ADORA2BPDE4B
SCHEMBL16084454 0.72 CYP11B2 (0.48) CDK9PDE7APIK3CAMTORHCAR1
SCHEMBL5775620 0.69 PDE4B (0.54) PDE4BPIK3CAHCAR1
SCHEMBL5778683 0.69 PDE4B (0.54) PDE4BPIK3CAHCAR1
SCHEMBL5775573 0.69 PDE4B (0.54) PDE4BPIK3CAHCAR1
SCHEMBL17481508 0.68 EGFR (0.34) PDE4BCDK5CDK5R1PDE7ANOS1
SCHEMBL16084171 0.67 CDK9 (0.48) ADORA2AADORA3ADORA1ADORA2BCCNT1
SCHEMBL16061224 0.64 HCAR1 (0.46) ADORA2AADORA3ADORA1ADORA2BCDK9
SCHEMBL16084282 0.64 CYP11B2 (0.46) ADORA2AADORA3ADORA1ADORA2BCCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-10-23 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KCNA7, KCNA2, KCNK17 ADORA2A 1224/4885ADORA3 601/4885ADORA1 903/4885
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA2A 1224/4885ADORA3 601/4885ADORA1 903/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA2A 1226/4885ADORA3 614/4885ADORA1 902/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA2A 1224/4885ADORA3 601/4885ADORA1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.